White House says MFN deals will cap Medicaid drug prices for all 50 states

The White House announced on September 18, 2026, that its agreements with pharmaceutical manufacturers will let all 50 State Medicaid programs obtain rebates so the final Medicaid price does not exceed the lowest price paid by other developed nations; the claim appears in a White House fact sheet.

What the White House provides as evidence; the fact sheet says the program covers hundreds of branded drugs across major classes including oncology, diabetes care and asthma; it cites one million free prescriptions of Eliquis already provided to Medicaid programs; it lists agreements with 26 manufacturers and says those deals cover 89% of the branded drug market.

The administration’s savings estimates and direct-to-consumer program; the White House cites the Council of Economic Advisers as estimating $64.3 billion in Medicaid drug-cost savings over the next decade, with $36.6 billion accruing to the Federal government and $27.6 billion to States; the fact sheet also says TrumpRx.gov users have saved more than $700 million and that 600,000 seniors saved $216 million on GLP-1 drugs after gaining access at $50 per month.

Practical consequence if the claims hold; lower net prices for Medicaid prescriptions would reduce drug spending for State and Federal budgets and could free state funds for other services, according to the administration’s modeling; TrumpRx.gov, if sustained, would provide a route for direct consumer savings at MFN-equivalent prices.

Limits and uncertainties; these are White House assertions and administration estimates; models are not presented in full in the fact sheet and have not been independently verified in the document; the fact sheet does not explain how participation will be enforced or whether states must opt in; it does not show the underlying rebate contracts, legal analyses or detailed budget scoring.

Competing explanations and risks; manufacturers could change launch, supply or pricing strategies in response, which could alter projected savings; this is an inference based on typical market responses rather than a claim in the fact sheet; the White House also states that an interagency agreement with the U.K. will raise U.K. net prices by 25% to protect U.S. MFN prices; that international outcome is presented as administration policy, not as an independently confirmed international commitment.

What to watch next; the Journal will look for Centers for Medicare & Medicaid Services guidance to states, detailed budget scoring from independent analysts or the Congressional Budget Office, any manufacturer notices about supply or pricing changes, and state decisions about program participation.

See something we should correct? Read our corrections policy.